Fetal EchoScan vs EchoNext
AI Verdict
Choose Fetal EchoScan if…
Choose Fetal EchoScan if your practice focuses on prenatal care and requires AI-powered assistance during fetal ultrasound examinations. This tool is ideal for maternal-fetal medicine specialists and cardiologists aiming to improve the prenatal detection of congenital heart defects, ensure comprehensive exams, and optimize workflow during real-time scans. It helps reduce false-negative and false-positive errors in CHD detection and integrates seamlessly with existing ultrasound machines.
View Fetal EchoScan →Choose EchoNext if…
Choose EchoNext if your practice seeks an efficient, non-invasive method to screen for hidden structural heart disease in a broad patient population using standard ECGs. This tool is well-suited for cardiologists, family medicine practitioners, and internal medicine specialists who need to identify risks for heart failure, valve disease, and pulmonary hypertension, potentially before symptoms appear. Its deployment through a clinical decision support platform allows for broad access, from major hospitals to community practices.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Fetal EchoScan | EchoNext |
|---|---|---|
| Pricing | Contact for pricing | Starts at $600/month |
| Deployment | Cloud-based software-only device, integrates with existing ultrasound workflows. | Available through the OpenEvidence clinical decision support platform. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
| HIPAA | Unknown | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Fetal EchoScanFetal EchoScan offers real-time guidance and feedback during ultrasound scans, with a cart-side tablet display for immediate AI analysis and alerts, which directly enhances the sonographer's workflow and confidence. EchoNext, while integrating with the OpenEvidence platform, doesn't specify real-time interactive features during the ECG acquisition itself, focusing more on post-acquisition analysis.
Clinical Value
EchoNextEchoNext has demonstrated high accuracy in detecting a range of structural heart problems, outperforming cardiologists in head-to-head comparisons, and has been credited with guiding care that led to a heart transplant. Fetal EchoScan shows strong performance in detecting major CHDs and reducing false positives/negatives, and improving exam completeness, but EchoNext's direct impact on patient outcomes, such as facilitating a heart transplant, highlights a higher level of demonstrated clinical value.
Pricing & Value
EchoNextEchoNext provides transparent tiered pricing starting at $600/month, with details on discounts and add-ons, allowing potential customers to understand costs upfront. Fetal EchoScan requires contacting the vendor for pricing, which lacks transparency and makes it difficult to assess its value proposition without direct engagement.
Enterprise Readiness
EchoNextEchoNext is deployed through the OpenEvidence clinical decision support platform, which is used by a significant number of U.S. physicians, indicating a robust and scalable deployment strategy for broad access across various clinical settings. Fetal EchoScan is cloud-based and integrates with existing ultrasound workflows, but its enterprise reach and established platform integration are not as explicitly detailed as EchoNext's.
Innovation
EchoNextEchoNext is highlighted as the world's first FDA-approved AI detection tool to analyze ECGs for hidden structural heart disease, representing a novel approach to early detection using a widely available and inexpensive test. While Fetal EchoScan offers innovative AI-driven support for prenatal ultrasound, EchoNext's ability to extract complex structural heart disease information from a standard ECG, a test traditionally not used for this purpose, demonstrates a more significant innovative leap.
Support & Docs
TieBoth tools are FDA-cleared, implying a certain level of documentation and regulatory support. However, specific details regarding ongoing customer support, training programs, or publicly available documentation (beyond product descriptions and clinical studies) are not provided for either tool in the given information or readily available through general web searches. Therefore, it is difficult to distinguish between the two in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Fetal EchoScan | EchoNext |
|---|---|---|
| Tool Name | Fetal EchoScan | EchoNext |
| Company | Brightheart | Pathway Labs |
| Description | FDA-cleared AI-powered ultrasound screening software that assists clinicians in the prenatal detection of congenital heart defects, ensuring comprehensive exams and optimizing workflow. | FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Primary Function | Prenatal detection of congenital heart defects (CHDs) using ultrasound. | Detection of hidden structural heart disease from standard ECGs. |
| Categories | Cardiology AI, OB/GYN AI | Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics |
| Specialties | Cardiology, Maternal-Fetal Medicine, Radiology | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
| Key Features | AI-driven support for prenatal ultrasound examinations, automated detection of congenital heart defects (CHDs), real-time guidance and feedback during ultrasound scans, ensures exam completeness and standardization of fetal heart assessments, reduces false-negative and false-positive errors in CHD detection, optimized workflow and faster reading times for clinicians, seamless integration with existing ultrasound machines and reporting solutions (DICOM compatible), cart-side tablet display for real-time AI analysis and alerts. | AI-powered ECG analysis, detection of hidden structural heart disease, identifies heart failure risk, screens for valve disease, detects pulmonary hypertension indicators, utilizes standard 12-lead ECGs, FDA-cleared technology, non-invasive diagnostic support. |
Videos
Demos, reviews, and walkthroughs featuring Fetal EchoScan and EchoNext.
Frequently Asked Questions
More Comparisons
More matchups featuring Fetal EchoScan or EchoNext
Backers
Who funded each tool's parent company.